SCHEMBL1625539

SCHEMBL1625539

CNCCc1nccs1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20298653 0.88 ADRB2 (0.39)
SCHEMBL10293025 0.80 DRD4 (0.40)
SCHEMBL8671012 0.79 FDPS (0.47)
SCHEMBL20691085 0.79
SCHEMBL16869717 0.79
SCHEMBL178402 0.78
SCHEMBL1844674 0.77 ADRB2 (0.40)
Hydrochloric Acid SCHEMBL28187462 0.77
SCHEMBL21593827 0.76 DRD4 (0.38)
SCHEMBL3421030 0.76 CYP2C19 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066040-A1 EP4 INHIBITORS AND USE THEREOF ARRYS THERAPEUTICS INC (US) 2024-02-29 US claimed
US-20210290641-A1 EP4 INHIBITORS AND USE THEREOF ASKAT INC. (JP) 2021-09-23 US claimed
EP-3781162-A1 EP4 INHIBITORS AND USE THEREOF Arrys Therapeutics, Inc. (US) 2021-02-24 EP claimed
CN-112292128-A EP4 inhibitors and uses thereof 阿瑞斯医疗有限公司 2021-01-29 CN claimed
WO-2019204257-A1 EP4 INHIBITORS AND USE THEREOF Arrys Therapeutics, Inc. (US) 2019-10-24 WO claimed
US-20190314390-A1 EP4 INHIBITORS AND USE THEREOF ASKAT INC. (JP) 2019-10-17 US claimed
US-20070155732-A1 Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents PFIZER INC. 2007-07-05 US claimed
US-7141580-B2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents PFIZER INC. (US) 2006-11-28 US claimed
EP-1326864-B1 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMA (JP) 2006-03-15 EP claimed
US-20040181059-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ASKAT INC. (JP) 2004-09-16 US claimed
US-6710054-B2 CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS PFIZER INC 2004-03-23 US claimed
EP-1326864-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2003-07-16 EP claimed
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ASKAT INC. (JP) 2002-08-08 US claimed
WO-2002032900-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO claimed
US-12454547-B2 Steroidal compositions and methods of treating lipogenic cancers Asteroid Therapeutics (US) 2025-10-28 US disclosed
US-20240066040-A1 EP4 INHIBITORS AND USE THEREOF ARRYS THERAPEUTICS INC (US) 2024-02-29 US disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 US disclosed
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PFIZER PHARMACEUTICALS INC. (JP) 2002-06-20 US disclosed
WO-2002032422-A2 EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO disclosed
WO-2002032900-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO disclosed